Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Iris bungei extract is a natural product derived from the plant Iris bungei Maxim., which is native to China and Mongolia and traditionally used in Mongolian medicine for various conditions such as inflammation and cancer[2][3]. The methanol extract of Iris bungei has been shown to promote brown adipocyte differentiation by increasing lipid accumulation, upregulating brown adipocyte-specific genes (including UCP-1, PGC-1α, PRDM16), and enhancing mitochondrial biogenesis and function[3]. These effects suggest potential applications in managing obesity and metabolic disorders. Phytochemical studies indicate that the plant contains phenolic compounds such as flavonoids, phenolic acids, quinone derivatives (e.g., 3-hydroxyirisquinone), peltogynoids, and other bioactive molecules with antioxidant properties[1][4][5][6]. The precise mechanism of action appears to involve modulation of gene expression related to adipogenesis and mitochondrial activity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on iris bungei extract.